Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain 5 (ADAM5) is a member of the ADAM (A Disintegrin And Metalloproteinase) family, which comprises transmembrane proteins with metalloprotease, disintegrin, cysteine-rich, and epidermal growth factor-like domains. However, in humans, ADAM5 exists only as a pseudogene (ADAM5P) and does not encode a functional, catalytically active protein. Thus, it does not contribute to known physiological or pathological processes in humans. Functional ADAM genes are important for cell-cell interactions, ectodomain shedding, and development, but these roles are carried out by other ADAM family members, such as ADAM10 and ADAM17, in humans. It is critical to distinguish the human ADAM5 (pseudogene) from its counterparts in other species, where it may have functional importance, particularly in reproductive biology in rodents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 5 (ADAM5).